Related Experiment Video
Updated: Aug 19, 2026

Replication of the Ordered, Nonredundant Library of Pseudomonas aeruginosa strain PA14 Transposon Insertion Mutants
Published on: May 4, 2018
[Pseudomonas aeruginosa--a significant hospital pathogen and resistance to carbapenem]
1Zavod za klinicku mikrobiologiju i bolnicke infekcije, Opća bolnica Sveti Duh, Zagreb, Hrvatska.
Abstract:
Pseudomonas aeruginosa (P. aeruginosa) is an etiologic agent of nosocomial infections of various localizations. The frequency of infections is a consequence of an increased number of immunocompromised patients, large surgical interventions, long-term hospital care and virulence factors of the bacterium. The use of carbapenems in the treatment of infections caused by P. aeruginosa and other gram-negative bacteria entail an unfortunate consequence of creating resistance to carbapenems. P. aeruginosa exhibits numerous mechanisms of resistance and is singularly problematic for combining intrinsic resistance and acquired resistance due to multiple mutations. It is also a carrier of the multiple-resistance plasmide. Carbapenems are a class of beta-lactam antibiotics with broad-spectrum activity to gram-positive, gram-negative and strictly anaerobic bacteria. The resistance of P. aeruginosa to carbapenems is complex and heterogeneous. It is determined by weakening the penetration through the outer membrane due to the loss of porin D2, decrease in the accumulation of antibiotic in the cell consequentially to active efflux due to hyperproduction of proteins, hydrolysis of carbapenem by specific metallo-beta-carbapenemases, and alteration in the target area of antibiotic activity on the bacterial cell. The loss of porin D2 results in resistance to imipenem with MIC values of 8.0-32.0 microg/mL. Selective low-level resistance to meropenem in the hyperproduction of the efflux system results in MIC values of 2.0-4.0 microg/mL. A high-level resistance to carbapenems with MIC values above 128 microg/mL for imipenem and meropenem is a consequence of the secretion of IMP and VIM series beta-carbapenemases. The frequency of resistance to P. aeruginosa to carbapenems varies worldwide from 15% to > or = 35%. In Croatia, resistance to carbapenems in the year 2003 was estimated to 12%. The problems in clinical practice are the increased resistance of P. aeruginosa to carbapenems, the presence of beta-carbapenemases and acquisition of these enzymes in certain types of Enterobacteriacea. The problems in laboratory practice are those of precise determination of the level and phenotype resistance of P. aeruginosa to carbapenems.
Insights
Pseudomonas aeruginosa resistance to carbapenems is a growing global threat, driven by complex resistance mechanisms. Understanding these mechanisms is crucial for effective treatment of nosocomial infections.
Area of Science:
- Microbiology
- Infectious Diseases
- Antimicrobial Resistance
Background:
- Pseudomonas aeruginosa (P. aeruginosa) is a significant cause of hospital-acquired infections.
- Increasing numbers of immunocompromised patients and invasive procedures contribute to P. aeruginosa infections.
- Carbapenem antibiotics, crucial for treating gram-negative infections, face rising resistance from P. aeruginosa.
Purpose of the Study:
- To elucidate the multifaceted mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
- To highlight the clinical and laboratory challenges posed by P. aeruginosa carbapenem resistance.
Main Methods:
- Analysis of P. aeruginosa resistance mechanisms, including porin loss, efflux pumps, and beta-lactamase production.
- Review of minimum inhibitory concentration (MIC) values associated with specific resistance phenotypes.
- Examination of global and regional prevalence data for carbapenem-resistant P. aeruginosa.
Main Results:
- Resistance mechanisms include reduced antibiotic penetration (porin D2 loss), decreased intracellular accumulation (efflux pumps), and enzymatic hydrolysis (metallo-beta-carbapenemases like IMP and VIM).
- Specific resistance levels correlate with distinct mechanisms: porin loss (imipenem MICs 8.0-32.0 µg/mL), efflux hyperproduction (meropenem MICs 2.0-4.0 µg/mL), and carbapenemase secretion (imipenem/meropenem MICs >128 µg/mL).
- Global carbapenem resistance rates in P. aeruginosa range from 15% to over 35%, with variations by region.
Conclusions:
- The complex and heterogeneous resistance of P. aeruginosa to carbapenems presents significant clinical challenges.
- The emergence and spread of carbapenemases, including their transfer to other Enterobacteriaceae, exacerbate the problem.
- Accurate laboratory determination of resistance levels and phenotypes is essential for patient management.
More Related Videos
Related Concept Videos
Mechanism of Antibiotic Resistance in MRSA
Clinical Significance of Antibiotic Resistance
Development of Antibiotic Resistance
Gene Regulation in Microbial Communities: Quorum Sensing
Atypical Pneumonia
Pneumonia I: Introduction

